CHRS
Coherus Oncology, Inc. Common Stock
Nasdaq · usd
Coherus Oncology, Inc. Common Stock (CHRS) trades at $0.3698 (-4.47%) as of 7:30:06 PM EST on Nov 20, 2026, -64.78% over the past month. Market cap is $57.15M, with 8.2 days to cover in short interest.
Stock performance
How Coherus Oncology, Inc. Common Stock (CHRS) stock has performed from one day to one year, with its 52-week range.
- 1D
- -4.47%
- 1W
- -29.63%
- 1M
- -64.78%
- YTD
- -73.96%
- 1Y
- -71.11%
- 52-wk range
- $0.36 – $2.62
Key statistics
Today's trading snapshot for CHRS: day range, open, previous close, volume and market cap.
- Day range
- $0.36 – $0.41
- Open
- $0.39
- Prev close
- $0.39
- Volume
- 2.52M
- Market cap
- $57.15M
- Shares out
- 154.5M
Valuation and profitability ratios: P/E, P/S, ROE
Valuation and profitability ratios for Coherus Oncology, Inc. Common Stock: P/E, P/S, P/B, ROE and more.
- P/E
- —
- P/S
- 1.07
- P/B
- 2.26
- P/FCF
- —
- ROE
- -538.4%
- ROA
- -79.5%
- Debt/Equity
- 2.08
- Div yield
- 0.00%
As of Nov 20, 2026
8-K filings
Material corporate events Coherus Oncology, Inc. Common Stock has disclosed to the SEC on Form 8-K.
- Quarterly earningsNov 9, 2026
On November 9, 2026, Coherus Oncology, Inc. (the "Company") issued a press release regarding its financial results for the quarter ended September 30, 2026.
- Clinical trial resultsOct 29, 2026
In second-line ESCC, 17 patients were safety evaluable and 8 were efficacy evaluable; in the 700 mg tagmokitug dose arm, the clinical benefit rate was 33.3%, cORR was 16.7%, and median progression-free survival was 5.5 months.
- Underwriting agreementAug 28, 2026
Under the Sales Agreement, the Agent may sell Shares by any method permitted by law deemed to be an "at the market offering" under Rule 415(a)(4) under the Securities Act of 1933, as amended (the "Securities Act"). The Company will pay the Agent a commission up to 3.0% of the gross proceeds from each sale of Shares and provide the Agent with customary indemnification and contribution rights.
- Debt retirementAug 17, 2026
A portion of the Tranche A Term Loan proceeds was used to repay all obligations under the Company's existing senior secured term loan facility (the "Prior Loan Agreement"), which accrued interest at a rate equal to 8.0%, plus a three-month SOFR rate per annum, and was scheduled to mature in May 2029.
- Credit facilityAug 17, 2026
The Company is party to the Loan and Security Agreement, dated as of August 12, 2026, with Innovatus Life Sciences Lending Fund I, L.P., as collateral agent, and the lenders thereunder (the 'Loan Agreement'), which contains certain restrictions on the disposition of the Legacy BioSim Assets and payments under the CVR.
CHRS short interest
How heavily CHRS is shorted: shares short, days to cover and average daily volume.
- Days to cover
- 8.2
- Short interest
- 12.71M
- Avg volume
- 1.55M
As of · reported to FINRA twice monthly.
CHRS news
The latest news and headlines about Coherus Oncology, Inc. Common Stock (CHRS).
- Here's Why Coherus Oncology (CHRS) Is a Great 'Buy the Bottom' Stock NowpositiveZacks Investment Research· Nov 18, 2026
- Coherus Oncology: 3 Key Takeaways for Long-Term InvestorsnegativeThe Motley Fool· Nov 10, 2026
- Coherus Oncology (CHRS) Reports Q3 Loss, Lags Revenue EstimatesnegativeZacks Investment Research· Nov 9, 2026
- Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026neutralGlobeNewswire Inc.· Jul 22, 2026
- Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)positiveGlobeNewswire Inc.· Jun 23, 2026
Frequently asked questions
What is the Coherus Oncology, Inc. Common Stock (CHRS) stock price today?
Coherus Oncology, Inc. Common Stock (CHRS) is trading at $0.3698 (-4.47% on the day) as of 7:30:06 PM EST on Nov 20, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.
What is Coherus Oncology, Inc. Common Stock?
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers.
What is the short interest in CHRS?
As of Oct 30, 2026, CHRS has 12.71M shares short and 8.2 days to cover.
What exchange is CHRS listed on?
Coherus Oncology, Inc. Common Stock (CHRS) trades on Nasdaq in USD, in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry.
Build with AI
Build an analysis of CHRS with your agent
Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.
Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a CHRS analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.